South Korea · Delayed Price · Currency is KRW BioNote Statistics
Total Valuation
BioNote has a market cap or net worth of KRW 563.57 billion. The enterprise value is 214.51 billion.
| Market Cap | 563.57B |
| Enterprise Value | 214.51B |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNote has 101.36 million shares outstanding. The number of shares has decreased by -0.49% in one year.
| Current Share Class | 101.36M |
| Shares Outstanding | 101.36M |
| Shares Change (YoY) | -0.49% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 58.37% |
| Owned by Institutions (%) | 0.19% |
| Float | 14.27M |
Valuation Ratios
The trailing PE ratio is 4.70.
| PE Ratio | 4.70 |
| Forward PE | n/a |
| PS Ratio | 5.03 |
| PB Ratio | 0.34 |
| P/TBV Ratio | 0.34 |
| P/FCF Ratio | 22.51 |
| P/OCF Ratio | 15.53 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.33, with an EV/FCF ratio of 8.57.
| EV / Earnings | 1.79 |
| EV / Sales | 1.91 |
| EV / EBITDA | 1.33 |
| EV / EBIT | 1.40 |
| EV / FCF | 8.57 |
Financial Position
The company has a current ratio of 39.00, with a Debt / Equity ratio of 0.00.
| Current Ratio | 39.00 |
| Quick Ratio | 36.41 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.15 |
| Debt / FCF | 0.15 |
| Interest Coverage | 60.73 |
Financial Efficiency
Return on equity (ROE) is 7.36% and return on invested capital (ROIC) is 0.66%.
| Return on Equity (ROE) | 7.36% |
| Return on Assets (ROA) | 0.64% |
| Return on Invested Capital (ROIC) | 0.66% |
| Return on Capital Employed (ROCE) | 1.00% |
| Revenue Per Employee | 375.99M |
| Profits Per Employee | 403.20M |
| Employee Count | 298 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 2.07 |
Taxes
In the past 12 months, BioNote has paid 13.28 billion in taxes.
| Income Tax | 13.28B |
| Effective Tax Rate | 9.95% |
Stock Price Statistics
The stock price has increased by +15.09% in the last 52 weeks. The beta is 0.98, so BioNote's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | +15.09% |
| 50-Day Moving Average | 5,765.60 |
| 200-Day Moving Average | 5,133.38 |
| Relative Strength Index (RSI) | 45.57 |
| Average Volume (20 Days) | 80,657 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioNote had revenue of KRW 112.04 billion and earned 120.16 billion in profits. Earnings per share was 1,182.12.
| Revenue | 112.04B |
| Gross Profit | 58.97B |
| Operating Income | 17.15B |
| Pretax Income | 133.43B |
| Net Income | 120.16B |
| EBITDA | 25.66B |
| EBIT | 17.15B |
| Earnings Per Share (EPS) | 1,182.12 |
Balance Sheet
The company has 352.91 billion in cash and 3.85 billion in debt, giving a net cash position of 349.06 billion or 3,443.69 per share.
| Cash & Cash Equivalents | 352.91B |
| Total Debt | 3.85B |
| Net Cash | 349.06B |
| Net Cash Per Share | 3,443.69 |
| Equity (Book Value) | 1.68T |
| Book Value Per Share | 16,544.53 |
| Working Capital | 402.92B |
Cash Flow
In the last 12 months, operating cash flow was 36.30 billion and capital expenditures -11.26 billion, giving a free cash flow of 25.04 billion.
| Operating Cash Flow | 36.30B |
| Capital Expenditures | -11.26B |
| Free Cash Flow | 25.04B |
| FCF Per Share | 247.03 |
Margins
Gross margin is 52.63%, with operating and profit margins of 15.30% and 107.24%.
| Gross Margin | 52.63% |
| Operating Margin | 15.30% |
| Pretax Margin | 119.09% |
| Profit Margin | 107.24% |
| EBITDA Margin | 22.90% |
| EBIT Margin | 15.30% |
| FCF Margin | 22.35% |
Dividends & Yields
This stock pays an annual dividend of 200.00, which amounts to a dividend yield of 3.62%.
| Dividend Per Share | 200.00 |
| Dividend Yield | 3.62% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 16.87% |
| Buyback Yield | 0.49% |
| Shareholder Yield | 4.20% |
| Earnings Yield | 21.32% |
| FCF Yield | 4.44% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNote has an Altman Z-Score of 7.91 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.91 |
| Piotroski F-Score | 6 |